Skip to content

Pharmacokinetics of Vancomycin in Adults Receiving ECMO

Pharmacokinetics and Posology of Vancomycin in Adults Receiving ECMO

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00281281
Enrollment
24
Registered
2006-01-24
Start date
2005-12-31
Completion date
2007-04-30
Last updated
2012-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extracorporeal Membrane Oxygenation

Keywords

Extracorporeal Membrane Oxygenation, vancomycin

Brief summary

1. Vancomycin is a drug that requires precise dosing and close monitoring to avoid drug toxicity. 2. There is limited data on the change of vancomycin pharmacokinetics in patients who need extracorporeal membrane oxygenation (ECMO). 3. This control trial is to understand: 1. whether the pharmacokinetics of vancomycin is influenced by the use ECMO 2. design the most appropriate dose of vancomycin in adult patients using ECMO.

Detailed description

1. Vancomycin is a drug that requires precise dosing and close monitoring to avoid drug toxicity. 2. Oftentimes it is used in intensive care units (ICU) for patients who need a life-saving machine for heart and lung failure called extracorporeal membrane oxygenation (ECMO). 3. There is limited data on the change of vancomycin pharmacokinetics in these patients. 4. This is a control trial using ICU patients who need vancomycin but not ECMO as a control to understand: 1. whether the pharmacokinetics of vancomycin is influenced by the use ECMO 2. design the most appropriate dose of vancomycin in adult patients using ECMO. 5. After the 4th dose of vancomycin, blood was drawn at appropriate time spots (1 mL each) to determine the time concentration curve and to calculate the pharmacokinetic parameters for 2 groups of patients to determine if there is any difference.

Interventions

DRUGvancomycin

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* \>18 y/o * receiving ECMO for study group * without ECMO for control group (sex, age, creatinine clearance match with study group)

Exclusion criteria

* severe burn (\>30-40% BSA) * receiving continuous renal replacement therapy or hemodialysis concurrently

Design outcomes

Primary

MeasureTime frame
pharmacokinetic parameters

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026